menu
    • menu
    [{"orgOrder":0,"company":"Mandos Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Adrabetadex","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Mandos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mandos Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mandos Health \/ Undisclosed"},{"orgOrder":0,"company":"Mandos Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Adrabetadex","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Mandos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mandos Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mandos Health \/ Undisclosed"},{"orgOrder":0,"company":"Mandos Health","sponsor":"INPDR","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Adrabetadex","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Mandos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mandos Health \/ INPDR","highestDevelopmentStatusID":"10","companyTruncated":"Mandos Health \/ INPDR"},{"orgOrder":0,"company":"Mandos Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Adrabetadex","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Mandos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mandos Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mandos Health \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Adrabetadex

    Menu

    Adrabetadex

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mandos Health

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Mandos Health

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adrabetadex

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Sponsor : INPDR

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            International Niemann-Pick Disease Registry and Mandos Health Announce New Research Collaboration Using Real-W...

                            Details : The partnership will provide Mandos Health with real-world evidence that will directly inform the development of its Niemann-Pick type C1 (NPC1) investigational product, VTS-270 (adrabetadex).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 16, 2023

                            Lead Product(s) : Adrabetadex

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : INPDR

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mandos Health

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Mandos Health

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adrabetadex

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease

                            Details : Adrabetadex is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Niemann-Pick Disease, Type C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 12, 2021

                            Lead Product(s) : Adrabetadex

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Mandos Health

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Mandos Health

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adrabetadex

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System

                            Details : Adrabetadex is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Niemann-Pick Disease, Type C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 23, 2018

                            Lead Product(s) : Adrabetadex

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Mandos Health

                            U.S.A arrow
                            VMX
                            Not Confirmed

                            Mandos Health

                            U.S.A arrow
                            VMX
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adrabetadex

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease

                            Details : Adrabetadex is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Niemann-Pick Disease, Type C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2015

                            Lead Product(s) : Adrabetadex

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.